

Oral Pathology in the 21st Century: Updates in Mucosal Disease

January 9, 2021 • 6 CE credits • Tuition \$300



About this Symposium

The Harvard School of Dental Medicine, with support from StrataDx, presents the latest in detection and treatment of mucosal disease. The lectures are designed to provide oral surgeons, periodontists, and endodontists further education on topics related to oral pathology.

After completing the courses, clinicians will have broader knowledge of:

- ✓ Diagnostic aspects and pitfalls of mucosal disease, use of steroids and other medications in the mouth, and common interpretations of radiographic findings
- ✓ Understanding of molecular findings in odontogenic cysts and tumors
- ✓ Introduction to new cancer therapy such as topical chemotherapy, check point inhibitor therapy and novel muco-adhesive agents

Scan to register:



<https://bit.ly/3o8Alof>

Lecture Schedule

No course prerequisites required. Please note times are EST.

9:00am-10:00am: Immunotherapy in Head and Neck Cancer by Glenn Hanna, MD

Educational Objectives:

- Gain an understanding of the cancer-immunity cycle
- Learn the mechanism of immune checkpoint inhibitors and how they are used in head and neck cancer
- Appreciate the spectrum of novel immunotherapeutics in development for cancer

10:00am-11:00am: Oral White Lesions and New Concepts of Oral Leukoplakia by Sook-Bin Woo DMD, FDSRCS (Edin)

Educational Objectives:

- Learn to distinguish between reactive white lesions and leukoplakia
- Understand that even lesions that do not show dysplasia already carry dysplasia and cancer mutations
- Learn the advantages and disadvantages of noninvasive techniques such as brush biopsy and autofluorescence for diagnosis of precancerous lesions
- Learn to use topical chemotherapy for vermilion dysplasias

11:00am-11:15am: Break

11:15am-12:15pm: Update on HPV and Molecular Changes in Odontogenic Cysts and Tumors by Sook-Bin Woo DMD, FDSRCS (Edin)

Educational Objectives:

- Understand the difference between smoking- and HPV-associated head and neck cancer
- Know that odontogenic keratocyst and odontogenic tumors as well as bone lesions cyst carry mutations
- Be aware that treatments for such lesions will change as a result of lesions carrying targetable mutations

12:15pm-1:00pm: Break

1:00pm-2:00pm: Guidelines for the Diagnosis and Management of Oral Ulcerative Conditions by Vikki Noonan DMD, DMSc

Educational Objectives:

- Gain an understanding of the etiology of a variety of common oral ulcerative conditions
- Define key clinical features that distinguish amongst oral ulcerative conditions
- Appreciate diagnostic strategies and therapeutic approaches for patient management

2:00pm-3:00pm: Interesting Cases in Oral Pathology: Systemic Diseases with Oral Manifestations by Vikki Noonan DMD, DMSc

Educational Objectives:

- Recognize that oral lesions may be the herald of systemic disease
- Understand the role of oral health care providers in the early detection of systemic conditions
- Gain insight regarding a selection of systemic conditions that may present with oral manifestations

3:00pm – 3:15pm: Break

3:15pm-4:15pm: Tips and Hints to Aid in Successful Radiographic Interpretation by Bernard Friedland, BDS, MSc JD

Educational Objectives:

- Learn to identify the radiographic features of lesions, including their location, borders, internal structure and effect on adjacent structures
- Learn to use those features to distinguish between normal anatomy, benign and malignant lesions in order to arrive at a differential diagnosis
- Gain an understanding of radiographic findings that indicate that a biopsy and/or treatment is required and those that do not require such follow-up, or that there is no urgency for a biopsy or treatment

4:15pm-4:30pm: Question & Answer, Closing Remarks

Course Faculty



Glenn Hanna, MD
Dana-Farber Cancer Institute

Dr. Hanna completed his fellowship training in hematology and medical oncology at Dana-Farber Cancer Institute in 2016. Prior to this, he earned his medical degree from Georgetown University School of Medicine in 2010, where he graduated summa cum laude, a member of Alpha Omega Alpha Honor Society and the Kober Medalist for academic excellence. He joined the faculty of the Center for Head and Neck Oncology in 2017. Dr. Hanna's clinical and translational research efforts are focused on both molecular and immunologic biomarker discovery to foster precision medicine approaches to treat head and neck cancers and improve patient outcomes. He maintains foundation and industry support to explore immuno-oncology approaches to treat head and neck cancers and high-risk oral precancerous lesions using novel combination immune checkpoint blockade, intra-tumoral injectables, and immune effector cell (IEC) therapies.

Conflict of Interest by Speaker: (Grant/Research Support) Bristol-Myers Squibb, Exicure, GlaxoSmithKline, NantKwest/Altor Bioscience, Kite Pharma, Regeneron, Sanofi Genzyme, Kartos Therapeutics, Elevar, ASCO/CCF, V Foundation, Gateway for Cancer Research: (Consultant/Honorarium) Regeneron, Sanofi Genzyme, Bristol-Myers Squibb, Maverick Therapeutics, Merck, Kura, Sanofi Genzyme, Bio-Rads, Prelude, Bicara, Exicur: (Other financial or materials support) expert witness for Aaronson Rappaport Feinstein & Deutsch, LLP



Sook-Bin Woo, DMD, FDSRCS (Edin)
Brigham and Women's Hospital
Dana Farber Cancer Institute

Dr. Woo is Associate Professor at Harvard School of Dental Medicine and graduate program director for oral and maxillofacial pathology. She received her oral pathology training in Indiana University and Harvard University, her head and neck pathology training at Long Island Jewish Medical Center, NY, and her oral medicine training at the Brigham and Women's Hospital. She is board-certified in both oral and maxillofacial pathology and oral medicine and is co-director of the Center for Oral Pathology at StrataDx, a pathology laboratory in Lexington, MA. She cares for patients at the Brigham and Women's Hospital and Dana Farber Cancer Institute. She has published many articles and the second edition of Atlas in Oral Pathology was released in fall 2016. She received the Distinguished Senior Faculty Award from the Harvard School of Dental Medicine in 2012.

Conflict of Interest by Speaker: (Grant/Research Support) Bristol Myers Squibb: (Consultant) Novartis, StrataDx



Vikki Noonan, DMD, DMSc
Boston University School of Dental Medicine
Boston Medical Center

Dr. Noonan is Associate Professor and Director of the Division of Oral Pathology at the Boston University Henry M. Goldman School of Dental Medicine and is an Associate Pathologist at StrataDx. She received her oral pathology training at Harvard University. She is a Fellow in the American Academy of Oral and Maxillofacial Pathology and is a Diplomate of the American Board of Oral and Maxillofacial Pathology. She has published extensively in the peer-reviewed literature and serves as a reviewer for several professional journals. Her clinical interests include the diagnosis and management of conditions affecting the oral mucosa and the jaws.

Conflict of Interest by Speaker: (Grant/Research Support) None Reported: (Consultant) StrataDx



Bernard Friedland, BDS, MScJD
Harvard School of Dental Medicine

Dr. Friedland earned his dental degree from University of Stellenbosch School of Dentistry and trained in oral radiology at the University of Toronto School of Dentistry. He is Associate Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine. He heads the Division of Oral and Maxillofacial Radiology and is responsible for teaching all pre- and post-doctoral radiology courses. He has published extensively in the peer-reviewed literature and serves as a reviewer for several professional journals. His clinical interests include the radiographic diagnosis of conditions affecting the jaws, as well as the use of digital imaging modalities in dentistry. He is a member of the Massachusetts Bar and has also published widely in the medico-legal and ethics literature.

Conflict of Interest by Speaker: None Reported

Register by December 31, 2020 to reserve your spot.

For more information visit the Harvard School of Dental Medicine at:

<https://bit.ly/3o8Alof>

- Cancellation 7 days before the course will be eligible for full refund. No refund will be made within 7 days of the course date.
- Webinar will be presented via Zoom. Session login will be sent to your registered email address on Tuesday, January 5, 2021.
- For more information contact Nkwazi Sabiti: omii@hdsdm.harvard.edu

ADA CERP® | Continuing Education
Recognition Program

Harvard School of Dental Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. The Harvard School of Dental Medicine designated this activity for 6 continuing education credits.

Symposium is supported by a grant from StrataDx. Participant information will be shared with StrataDx. Visit stratadx.com for more information.